Banner

Ovarian Cancer Drugs Global Market Report 2023 – By Tumor Type (Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex CordStromal Tumor), By Distribution Channel (Hospital Pharmacies, Drug Stores, Other Distribution Channels), By Drug Type (Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Other Drug Types) – Market Size, Trends, And Global Forecast 2023-2032

Starting Price : $5000.00 | Pages : 175 | Published : January 2023 | SKU CODE : r755 | Delivery Time: 2-3 business days | Format :


The ovarian cancer drugs refer to cancer drugs to treat ovarian cancer. Ovarian cancer is caused due to abnormal growth of cells in the ovary. This industry includes establishments that produce drugs used in chemotherapy, radiation, and surgery for treating ovarian cancer. The ovarian cancer drugs include Doxorubicin Hydrochloride Liposome, Evacet (Doxorubicin Hydrochloride Liposome), Cytoxan (Cyclophosphamide), Paraplat (Carboplatin), Taxol (Paclitaxel), Neosar (Cyclophosphamide) and others.

The main types of tumors in ovarian cancer drugs are epithelial ovarian cancer, ovarian low malignant potential tumor, germ cell tumor, and sex cord-stromal tumor. The most frequent kind of ovarian cancer is epithelial ovarian cancer. The majority of ovarian tumors (90 percent) are epithelial. Ovarian cancer that began in the epithelial layer protecting the ovary is known as epithelial ovarian cancer. The different types of drugs include alkylating agents, mitotic inhibitors, antirheumatics, antipsoriatics, VEGF/VEGF inhibitors, parp inhibitors, antineoplastics, others, and distribution channels such as hospital pharmacies, drug stores, others.

The ovarian cancer drugs market research report is one of a series of new reports from The Business Research Company that provides ovarian cancer drugs market statistics, including ovarian cancer drugs industry global market size, regional shares, competitors with an ovarian cancer drugs market share, detailed ovarian cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the ovarian cancer drugs industry. This ovarian cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The global ovarian cancer drugs market size will grow from $3.20 billion in 2022 to $3.71 billion in 2023 at a compound annual growth rate (CAGR) of 16.1%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global ovarian cancer drugs market size is expected to grow to $6.36 billion in 2027 at a CAGR of 14.4%.

The rising incidence of ovarian cancer is driving the ovarian cancer drugs market. Furthermore, ovarian cancer is recorded to be the eighth most commonly occurring cancer in women and the 18th most commonly occurring cancer across the globe. According to a study by The World Ovarian Cancer Coalition an estimated 55% rise is expected in the number of patients suffering from ovarian cancer by 2035. According to the Cancer Statistics in 2020, published by the American Cancer Society, about 1,806,590 new cancer cases and 606,520 deaths were expected in the USA. Thus, the increasing incidence of ovarian cancer cases across the globe drives the ovarian cancer drugs market growth.

The increasing use of biologics and targeted therapies is restraining the Ovarian Cancer drug market growth. Targeted therapies act as substitutes for drugs as they identify and attack cancer cells rather than destroying normal cells. For example, Bevacizumab is a targeted therapy biologics drug used to treat Ovarian Cancer. A targeted therapy drug, Zejula was approved by FDA for ovarian cancer, and many targeted therapy drugs such as PARP inhibitors (targeted therapy drug) are undergoing clinical trials and are in the drug pipeline. FDA has also approved Genentech’s biologics license for ovarian cancer drugs highlighting the fact many new companies are entering the biologics ovarian drug cancer market. Hence, the growing popularity of alternatives such as biologics and targeted therapies may hinder the growth of the ovarian cancer drugs market.

Drug manufacturing companies in the industry are increasingly innovating and developing combination drugs to treat ovarian cancer drugs. Combination drugs consist of two or more active pharmaceutical ingredients (APIs) that are combined into a single dosage form to treat complex medical conditions. The pharmaceutical companies in the ovarian cancer drugs market are investing in the research and development of innovative products such as combination drugs to reduce manufacturing costs, increase compliance and efficiency, improve medication concordance, increase profitability and reduce side effects. For instance, Roche's blockbuster tranquilize Avastin (bevacizumab), is a combination drug approved by FDA, with ingredients such as carboplatin and paclitaxel, which is utilized to treat advanced stage (III or IV) ovarian cancer.

The Ovarian cancer drugs market is governed by the regulatory framework of agencies such as the Food and Administration Agency (FDA) and the American Society of Clinical Oncology (ASCO). FDA's recommendation for the ovarian cancer drugs market in the form of guidelines is mentioned within the CFR's (Code for Federal Regulations) title number 21 under part 312, which contains sub-parts from subpart 'A' to subpart 'I'. The sub-part 'E' deals with the procedures designed to push the development, evaluation, and marketing of drugs related to therapies aimed to treat persons with life-threatening illnesses such as kidney cancer. Subpart 'E' also includes guidelines for the monitoring and evaluation of clinical trials of ovarian cancer drugs and other cancer drugs by agency officials to determine whether new treatments are safe and effective, or better than existing treatments. All companies operating in the ovarian cancer drugs industry are required to abide by the regulations under FDA.

In September 2021, BoehringerIngelheim, a Germany-based biopharmaceutical company acquired Abexxa Biologics for an undisclosed amount. Through this acquisition, BoehringerIngelheim expands its portfolio in the field of oncology for treating cancer through Abexxa’s technology and antibody-based drugs. Abexxa Biologics is a biopharmaceutical company developing cancer drugs and immuno-oncology and oncology research for advanced precision medicines for cancer that includes all cancer types along with ovarian cancer drugs.

Major players in the ovarian cancer drugs market are AstraZeneca, Roche, Tesaro, Clovis Oncology, BoehringerIngelheim, Amgen, GlaxoSmithKline, F. Hoffmann-La Roche AG, Bristol-Myers Squibb and Eli Lilly and Company.

North America was the largest region in the ovarian cancer drugs market in 2022. Middle East is expected to be the fastest-growing region in the global ovarian cancer drugs market during the forecast period. The regions covered in the global ovarian cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

The countries covered in the ovarian cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The ovarian cancer drugs market consists of sales of Paclitaxel, Cisplatin, Adriamycin PFS (Doxorubicin Hydrochloride), Carboplatin, Cyclophosphamide, and Platinol (Cisplatin). Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The global ovarian cancer drugs market is segmented -

1) By Tumor Type: Epithelial Ovarian Cancer, Ovarian Low Malignant Potential Tumor, Germ Cell Tumor, Sex Cord-Stromal Tumor

2) By Distribution Channel: Hospital Pharmacies, Drug Stores, Other Distribution Channels

3) By Drug Type: Alkylating Agents, Mitotic Inhibitors, Antirheumatics, Antipsoriatics, VEGF/VEGFR inhibitors, PARP inhibitors, Antineoplastics, Other Drug Types

    Table Of Contents

    1. Executive Summary

    2. Ovarian Cancer Drugs Market Characteristics

    3. Ovarian Cancer Drugs Market Trends And Strategies

    4. Ovarian Cancer Drugs Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Ovarian Cancer Drugs Market

    4.2 Ukraine-Russia War Impact On Ovarian Cancer Drugs Market

    4.3 Impact Of High Inflation On Ovarian Cancer Drugs Market

    5. Ovarian Cancer Drugs Market Size And Growth

    5.1. Global Ovarian Cancer Drugs Historic Market, 2017-2022, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Ovarian Cancer Drugs Forecast Market, 2022-2027F, 2032F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Ovarian Cancer Drugs Market Segmentation

    6.1. Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Epithelial Ovarian Cancer

    Ovarian Low Malignant Potential Tumor

    Germ Cell Tumor

    Sex Cord-Stromal Tumor

    6.2. Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Hospital Pharmacies

    Drug Stores

    Other Distribution Channels

    6.3. Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    Alkylating Agents

    Mitotic Inhibitors

    Antirheumatics

    Antipsoriatics

    VEGF/VEGFR inhibitors

    PARP inhibitors

    Antineoplastics

    Other Drug Types

    7. Ovarian Cancer Drugs Market Regional And Country Analysis

    7.1. Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    7.2. Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8. Asia-Pacific Ovarian Cancer Drugs Market

    8.1. Asia-Pacific Ovarian Cancer Drugs Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.3. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    8.4. Asia-Pacific Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    9. China Ovarian Cancer Drugs Market

    9.1. China Ovarian Cancer Drugs Market Overview

    9.2. China Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.3. China Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    9.4. China Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F,$ Billion

    10. India Ovarian Cancer Drugs Market

    10.1. India Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.2. India Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    10.3. India Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11. Japan Ovarian Cancer Drugs Market

    11.1. Japan Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.2. Japan Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    11.3. Japan Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12. Australia Ovarian Cancer Drugs Market

    12.1. Australia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.2. Australia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    12.3. Australia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13. Indonesia Ovarian Cancer Drugs Market

    13.1. Indonesia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.2. Indonesia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    13.3. Indonesia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14. South Korea Ovarian Cancer Drugs Market

    14.1. South Korea Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.2. South Korea Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    14.3. South Korea Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15. Western Europe Ovarian Cancer Drugs Market

    15.1. Western Europe Ovarian Cancer Drugs Market Overview

    15.2. Western Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.3. Western Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    15.4. Western Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16. UK Ovarian Cancer Drugs Market

    16.1. UK Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.2. UK Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    16.3. UK Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17. Germany Ovarian Cancer Drugs Market

    17.1. Germany Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.2. Germany Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    17.3. Germany Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18. France Ovarian Cancer Drugs Market

    18.5. France Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.6. France Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    18.7. France Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19. Eastern Europe Ovarian Cancer Drugs Market

    19.1. Eastern Europe Ovarian Cancer Drugs Market Overview

    19.2. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.3. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    19.4. Eastern Europe Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20. Russia Ovarian Cancer Drugs Market

    20.1. Russia Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.2. Russia Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    20.3. Russia Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21. North America Ovarian Cancer Drugs Market

    21.1. North America Ovarian Cancer Drugs Market Overview

    21.2. North America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.3. North America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    21.4. North America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22. USA Ovarian Cancer Drugs Market

    22.1. USA Ovarian Cancer Drugs Market Overview

    22.2. USA Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.3. USA Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    22.4. USA Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23. South America Ovarian Cancer Drugs Market

    23.1. South America Ovarian Cancer Drugs Market Overview

    23.2. South America Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.3. South America Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    23.4. South America Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24. Brazil Ovarian Cancer Drugs Market

    24.1. Brazil Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.2. Brazil Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    24.3. Brazil Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25. Middle East Ovarian Cancer Drugs Market

    25.1. Middle East Ovarian Cancer Drugs Market Overview

    25.2. Middle East Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.3. Middle East Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    25.4. Middle East Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26. Africa Ovarian Cancer Drugs Market

    26.1. Africa Ovarian Cancer Drugs Market Overview

    26.2. Africa Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.3. Africa Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    26.4. Africa Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion

    27. Ovarian Cancer Drugs Market Competitive Landscape And Company Profiles

    27.1. Ovarian Cancer Drugs Market Competitive Landscape

    27.2. Ovarian Cancer Drugs Market Company Profiles

    27.2.1. AstraZeneca

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Roche

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Tesaro

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Clovis Oncology

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. Boehringer Ingelheim

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Ovarian Cancer Drugs Pipeline Analysis

    29. Key Mergers And Acquisitions In The Ovarian Cancer Drugs Market

    30. Ovarian Cancer Drugs Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Table 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Table 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Table 65: AstraZeneca Financial Performance
  • Table 66: Roche Financial Performance
  • Table 67: Tesaro Financial Performance
  • Table 68: Clovis Oncology Financial Performance
  • Table 69: Boehringer Ingelheim Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2017-2022, $ Billion
  • Figure 2: Global Forecast Market Growth, 2022-2027F, 2032F, $ Billion
  • Figure 3: Global Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 4: Global Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 5: Global Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 6: Global Ovarian Cancer Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 7: Global Ovarian Cancer Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 8: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 9: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 10: Asia-Pacific, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 11: China, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 12: China, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 13: China, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 14: India, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 15: India, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 16: India, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 17: Japan, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 18: Japan, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 19: Japan, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 20: Australia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 21: Australia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 22: Australia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 23: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 24: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 25: Indonesia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 26: South Korea, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 27: South Korea, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 28: South Korea, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 29: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 30: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 31: Western Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 32: UK, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 33: UK, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 34: UK, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 35: Germany, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 36: Germany, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 37: Germany, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 38: France, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 39: France, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 40: France, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 41: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 42: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 43: Eastern Europe, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 44: Russia, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 45: Russia, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 46: Russia, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 47: North America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 48: North America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 49: North America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 50: USA, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 51: USA, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 52: USA, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 53: South America, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 54: South America, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 55: South America, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 56: Brazil, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 57: Brazil, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 58: Brazil, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 59: Middle East, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 60: Middle East, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 61: Middle East, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 62: Africa, Ovarian Cancer Drugs Market, Segmentation By Tumor Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 63: Africa, Ovarian Cancer Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 64: Africa, Ovarian Cancer Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2017-2022, 2022-2027F, 2032F, $ Billion
  • Figure 65: AstraZeneca Financial Performance
  • Figure 66: Roche Financial Performance
  • Figure 67: Tesaro Financial Performance
  • Figure 68: Clovis Oncology Financial Performance
  • Figure 69: Boehringer Ingelheim Financial Performance
View Report
View Report
View Report
View Report
View Report
View Report
View Report
View Report